Orale Kontrazeptiva bei BRCA1-und BRCA2-Mutationsträgerinnen

Marion Kiechle

  1. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013 Jun 5; 105(11): 812–22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
  2. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (New York, N.Y.) 302: 643–646.
  3. Antoniou AC, Beesley J, Mcguffog L et al. (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer research 70: 9742–9754
  4. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA : the journal of the American Medical Association 304: 967–975.
  5. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutation. N Engl J Med 2001; 345: 159–64.
  6. Havrilesky LJ, Gierisch JM, Moorman PG et al (2013). Oral contraceptive use for the primary prevention of ovarian cancer. Evidence report/technology assessment no. 212. (Prepared by the Duke Evidence-based Practice Center under contract no. 290-2007-10066-I.) AHRQ Publication No. 13-E002-EF. Agency for Healthcare Research and Quality, Rockville
  7. Schmidmayer M, Seifert-Klauss V, Kiechle M. Pille und Krebsrisiko. Gynäkologische Endokrinologie 2014; 12: 138–143.
  8. Narod SA, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998 Aug 13; 339(7): 424–8.
  9. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. JCO 2013 Nov 20; 31(33): 4188–98.
  10. McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, West DW, Whittemore AS. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004 Oct 1; 160(7): 613–8.
  11. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Struewing JP, Tucker MA, Wacholder S; National Israel Ovarian Cancer Study Group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 26; 345(4): 235–40.
  12. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal and Endometrial Cancers: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2013 Oct 8.

Aktuelle Standards – Update 2014 Zielgerichtete Therapien beim Mammakarzinom

Nadia Harbeck

  1. AGO-Kommission “Mamma”. Empfehlungen 2014 für die Behandlung des primären und des metastasierten Mammakarzinoms: www.ago-online.de
  2. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013 Jul;14(8):741–8.
  3. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021–8.
  4. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164–72.
  5. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011 Sep 1;29(25):3351–7.
  6. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633–40.
  7. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25–32.
  8. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–84.
  9. Food and Drug Administration (FDA). Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. May 2012. www.fda.gov
  10. Piccart-Gebhart M, Holmes AP, de Azambuja E, Di Cosimo S, Swaby R, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios C, Gelber R, Eidtmann H, Baselga J. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). SABCS 2014: S1–01.
  11. Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, Zujewski JA, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D. Gelber, Edith A. PerezFirst results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA4)
  12. Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, Harbeck N. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013 Aug 19;14(1):261.
  13. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869–78.
  14. Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Oct;25(10):1979–87.
  15. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461–71.
  16. Swain S, Kim S, Cortes J,  Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes  MC, Baselga J. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ESMO 2014: 350O_PR
  17. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783–91.
  18. Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):689–99.
  19. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585–92
  20. Harbeck N, Wuerstlein R. Optimal Sequencing of Anti-HER2 Therapy throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations. Drugs. 2013 Oct;73(15):1665–80.
  21. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520–9.
  22. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012 Aug 1;30(22):2718–24.
  23. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013 Jan 10;31(2):195–202.
  24. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Breazna A, Kim ST, Randolph S, Slamon DJ. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (bC). SABCS 2012: S1–6.

Interview mit Prof. Gennari – Kinderwunschbehandlung und Brustkrebsrisiko

Breast cancer incidence after hormonal infertility treatments: systematic review and meta-analysis of population based studies
Alessandra Gennari1, Mauro Costa2, Laura Paleari3, Matteo Puntoni1, Maria Pia Sormani4, Andrea De Censi1, Paolo Bruzzi3
1Medical Oncology, Galliera Hospital, Genoa;
2
Reproductive Medicine, Evangelico International Hospital, Genoa; 3Epidemiology and Biostatistics, IRCCS A.O.U. San Martino-National Cancer Institute, Genoa;        
4
DISSAL University of Genoa, Genoa, Italy

  1. San Antonio Breast Caner Symposium 2013, S5-08; Die Originalslides finden Sie z.B. unter web.oncoletter.de
  2. Int J Cancer 2014 Juli 9; Risk of breast cancer following fertility tratment – a registry based cohort study of parous women in Norway; Reigstad MM et al
  3. Hum Reprod Update 2014 Jan-Feb:2081:106-23; IVF and breast cancer: a systematic review and meta-analysis; Sergentanis TN et al

Hormonelle Diabetes-Prävention als gynäkologische Herausforderung

J. M. Wenderlein

  1. Diabetes-Atlas 6. Auflage 2013, Jahreskongress der International Diabetes Federation (IDF) 12/2013 Melbourne
  2. Haak T Editorial  Die nationale Diabetes-Katastrophe ÄBW 5 2012. S.186
  3. Destatis: Gesundheitsausgaben 2012
  4. Ewertz M. at al. Effect of Obesity on the Prognosis after Early-Stage Breast Cancer J. of Clinical Oncology 2011; 29(28): 3730–3738
  5. Chow E. et al. Risk of cardiac arrhythmias during hypoglycemia in patients with typ 2 diabetes and cardiovascular risk. Diabetes 2014;
    63:1738-1747
  6. Sugiyama T et al. Different Time Trends of Caloric and Fat Intake Between Statin Users and Nonusers Among US-Adults. Gluttony in the Time of Statins? JAMA Intern Med 2014; Online 24.April, doi: 10.1001/jamainternmed 2014, 1927
  7. Finegold JA. et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drugs ?Systematic review of randomized placebo-controlled trials to aid individual patient choice. Europ J of Preventive Cardiology. April 2014: 21; 464–474
  8. Herring S.J. et al. Objektively measured sleep duration and hypoglycemia in pregnancy. Sleep Med. 2014; 15: 51–55
  9. Williamson JD et al. Cognitive Funktion and Brain Structure in Persons With Type 2 Diabetes Mellitus A Randomized Clinical Trial. JAMA Internal Medicine 2014 online 3. February
  10. Lucas R. A. et al.Brain blood flow and cardiovascular responses to hot flasches in postmenopausal women.Menopause 20 (2013) 299–304
  11. Peters S.A. et al. Diabetes as a risk faktor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, includung 775.385 individuals and 12.539 strokes. Lancet 2014, online 7.3
  12. Michael E. et al. Risk Faktor Control vor Coronary Artery Disease Secundary Prevention in a Large Randomized Trials; J Am Coll Cardiol
    2013; 61(15): 1607–1615.
  13. Tseng CL et al.. Assessing Potential Glycemic Overtreatment in Persons at Hypoglycemic Risk.  JAMA Intern Med 2014 ;174 (2); 259–268
  14. Clarkson TB et al.. Timing hypothesis for postmenopausel hormone therapy: its origin, current status and future. Menopause 20 (2013) 342-353
  15. Haller H, et al. Glomeruläre Proteinurie. Der Nephrologe 2013; 8: 119–127
  16. American Diabetes Association Standards of medical care in diabetes – 2013; Diabetes Care 2013; 36 (Supplement)
  17. Mansi I. et al. Statins end Musculoskeletal Conditions ,Arthropathies and Injuries. JAMA Intern Med. 2013, online 3. Juni : doi 10. 1001/jamainternmed. 2013. 6184
  18. Snowling NJ. Et al. Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors in Type 2 Diabetic Patients.Diabetes Care 2006: 29(11): 2518–2527
  19. Hu J. et al. Gycemic index, glycemic load and cancer risk. Ann. Oncol. 2012, Online25.July: doi 10. 1093/annonc/mds 235
  20. Broussard J.L. Studies that restrict sleep show why a lack of shut-eye can lead to serious chronic disease Ann; Intern Med 2012; 157: 549–557

Hart aber fair: Der kleine Faktencheck zu HPV, Pap und Screening

Peter Hillemanns

  1. (a) Durst, M.; Gissmann, L.; Ikenberg, H.; zur Hausen, H., A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of National Academy of Sciences, U.S.A. 1983, 80, 3812-3815; (b) Hillemanns, P., Cervical cancer screening: the big step from morphology to molecular biology. Arch Gynecol Obstet 2013, 288 (5), 977.
  2. Marquardt, K.; Buttner, H. H.; Broschewitz, U.; Barten, M.; Schneider, V., Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause. Acta cytol 2011, 55 (5), 433–7.
  3. Kerek-Bodden, H.; Altenhofen, L.; Brenner, G. Abschlußbericht: Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten. 2009.
  4. Geyer, S.; Jaunzeme, J.; Hillemanns, P., Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Arch Gynecol Obstet 2014.
  5. Everett, T.; Bryant, A.; Griffin, M. F.; Martin-Hirsch, P. P.; Forbes, C. A.; Jepson, R. G., Interventions targeted at women to encourage the uptake of cervical screening. The Cochrane database of systematic reviews 2011,  (5), CD002834.
  6. Ronco, G.; Dillner, J.; Elfstrom, K. M.; Tunesi, S.; Snijders, P. J.; Arbyn, M.; Kitchener, H.; Segnan, N.; Gilham, C.; Giorgi-Rossi, P.; Berkhof, J.; Peto, J.; Meijer, C. J., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014, 383 (9916), 524–32.
  7. Arbyn, M.; Verdoodt, F.; Snijders, P. J.; Verhoef, V. M.; Suonio, E.; Dillner, L.; Minozzi, S.; Bellisario, C.; Banzi, R.; Zhao, F. H.; Hillemanns, P.; Anttila, A., Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. The Lancet. Oncology 2014, 15 (2), 172–83.
  8. Walboomers, J. M.; Jacobs, M. V.; Manos, M. M.; Bosch, F. X.; Kummer, J. A.; Shah, K. V.; Snijders, P. J.; Peto, J.; Meijer, C. J.; Munoz, N., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189 (1), 12–19.
  9. Arbyn, M.; Ronco, G.; Anttila, A.; Meijer, C. J.; Poljak, M.; Ogilvie, G.; Koliopoulos, G.; Naucler, P.; Sankaranarayanan, R.; Peto, J., Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30 Suppl 5, F88–99.
  10. Meijer, C. J.; Berkhof, J.; Castle, P. E.; Hesselink, A. T.; Franco, E. L.; Ronco, G.; Arbyn, M.; Bosch, F. X.; Cuzick, J.; Dillner, J.; Heideman, D. A.; Snijders, P. J., Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124 (3), 516–20.
  11. Cuzick, J.; Cadman, L.; Mesher, D.; Austin, J.; Ashdown-Barr, L.; Ho, L.; Terry, G.; Liddle, S.; Wright, C.; Lyons, D.; Szarewski, A., Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013, 108 (4), 908–13.
  12. Kitchener, H. C.; Almonte, M.; Thomson, C.; Wheeler, P.; Sargent, A.; Stoykova, B.; Gilham, C.; Baysson, H.; Roberts, C.; Dowie, R.; Desai, M.; Mather, J.; Bailey, A.; Turner, A.; Moss, S.; Peto, J., HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. The Lancet. Oncology 2009, 10 (7), 672–82.
  13. Petry, K. U.; Schmidt, D.; Scherbring, S.; Luyten, A.; Reinecke-Luthge, A.; Bergeron, C.; Kommoss, F.; Loning, T.; Ordi, J.; Regauer, S.; Ridder, R., Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011, 121 (3), 505–9.
  14. Carozzi, F.; Gillio-Tos, A.; Confortini, M.; Del Mistro, A.; Sani, C.; De Marco, L.; Girlando, S.; Rosso, S.; Naldoni, C.; Dalla Palma, P.; Zorzi, M.; Giorgi-Rossi, P.; Segnan, N.; Cuzick, J.; Ronco, G., Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. The Lancet. Oncology 2013, 14 (2), 168–76.
  15. Castle, P. E.; Solomon, D.; Schiffman, M.; Wheeler, C. M., Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005, 97 (14), 1066–71.
  16. Castle, P. E.; Stoler, M. H.; Wright, T. C., Jr.; Sharma, A.; Wright, T. L.; Behrens, C. M., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. The Lancet. Oncology 2011, 12 (9), 880–90.
  17. Saslow, D.; Solomon, D.; Lawson, H. W.; Killackey, M.; Kulasingam, S. L.; Cain, J.; Garcia, F. A.; Moriarty, A. T.; Waxman, A. G.; Wilbur, D. C.; Wentzensen, N.; Downs, L. S., Jr.; Spitzer, M.; Moscicki, A. B.; Franco, E. L.; Stoler, M. H.; Schiffman, M.; Castle, P. E.; Myers, E. R., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012, 62 (3), 147–72.
  18. Katki, H. A.; Kinney, W. K.; Fetterman, B.; Lorey, T.; Poitras, N. E.; Cheung, L.; Demuth, F.; Schiffman, M.; Wacholder, S.; Castle, P. E., Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. The Lancet. Oncology 2011, 12 (7), 663–72.
  19. Luyten, A.; Buttmann-Schweiger, N.; Luyten, K.; Mauritz, C.; Reinecke-Luthge, A.; Pietralla, M.; Meijer, C. J.; Petry, K. U., Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. International journal of cancer. Journal international du cancer 2014, 135 (6), 1408–16.
  20. Hillemanns, P., HPV-Impfstoff der Zweiten Generation: Gegen neun Virustypen gerichtet. Dtsch Arztebl 2013, 110 (A-2479 / B-2183 / C-2102), 51–52.
  21. Joura, E. A.; team., s., Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. In EUROGIN, Florence, Italy, 2013; Vol. SS 8-4, p 102.